FDA Determines Regulatory Review Period for TECENTRIQ Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has determined the regulatory review period for the patent extension of TECENTRIQ, a human biological product, following a submission to the U.S. Patent and Trademark Office (USPTO). This determination is published as a required notice.